Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing

Zhu,Xidan; Feng,Jia; Fu,Wenguang; Shu,Xiaojia; Wan,Xue; Liu,Jinbo

doi:10.3892/ijmm.2020.4543

Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing

Authors:
- Xidan Zhu
- Jia Feng
- Wenguang Fu
- Xiaojia Shu
- Xue Wan
- Jinbo Liu
View Affiliations

Affiliations: Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
Published online on: March 16, 2020 https://doi.org/10.3892/ijmm.2020.4543
Pages: 1838-1850
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to the chemotherapeutic drug cisplatin has been documented in various types of cancer, while the increased expression of β‑catenin has been observed in cisplatin‑resistant ovarian cancer. However, the involvement of β‑catenin in cisplatin resistance is unclear. The present study investigated the antitumor effect of cisplatin on the proliferation, invasion and apoptosis of breast cancer (BC) cells following β‑catenin silencing in BC, which is the most frequent type of malignancy among women. The expression of β‑catenin in BC tissues and cell lines was measured by reverse transcription‑quantitative polymerase chain reaction, and the association between expression levels and clinical characteristics was statistically analyzed. The viability of BC cell lines treated with siR‑β‑catenin or with siR‑β‑catenin and cisplatin in combination was determined using a Cell Counting Kit‑8 assay. The migratory and invasive abilities of BC cells treated with both siR‑β‑catenin and cisplatin were examined with Transwell assays. The CD44 antigen/intercellular adhesion molecule 1 expression ratio, cell cycle distribution and apoptosis levels of BC cells treated with siR‑β‑catenin and cisplatin in combination were detected by flow cytometry. The expression levels of apoptosis‑associated proteins, including caspase‑3/9, in the BC cells treated with both siR‑β‑catenin and cisplatin were investigated by western blot analysis. The levels of apoptosis in the BC cells following combined treatment with siR‑β‑catenin and cisplatin was further quantified by Hoechst 33342 staining. β‑catenin was identified to be highly expressed in BC tissues and cell lines and was associated with pathological stage and lymph node status. Following knockdown of β‑catenin expression, cisplatin treatment suppressed the viabilities, and the migratory and invasive capabilities of the T47D and MCF‑7 cells, and induced extensive apoptosis. β‑catenin knockdown upregulated caspase‑3/9 levels following cisplatin treatment and induced the apoptosis of T47D and MCF‑7 cells. In conclusion, β‑catenin may be of value as a therapeutic target during cisplatin treatment in patients with BC treated with cisplatin.

View Figures

View References

1	Di Cosimo S and Baselga J: Management of breast cancer with targeted agents: Importance of heterogeneity. [corrected]. Nat Rev Clin Oncol. 7:139–147. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bostner J, Ahnström-Waltersson M, Fornander T, Skoog L, Nordenskjöld B and Stål O: Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in post-menopausal breast cancer. Oncogene. 26:6997–7005. 2007. View Article : Google Scholar : PubMed/NCBI
3	Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R and Sutherland RL: EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene. 15:1617–1623. 1997. View Article : Google Scholar : PubMed/NCBI
4	Mukherjee S and Conrad SE: c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem. 280:17617–17625. 2005. View Article : Google Scholar : PubMed/NCBI
5	Fujita T, Liu W, Doihara H and Wan Y: An in vivo study of Cdh1/APC in breast cancer formation. Int J Cancer. 125:826–836. 2009. View Article : Google Scholar : PubMed/NCBI
6	Lei H, Sjoberg-Margolin S, Salahshor S, Werelius B, Jandakova E, Hemminki K, Lindblom A and Vorechovsky I: CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer. 98:199–204. 2002. View Article : Google Scholar : PubMed/NCBI
7	Feinberg AP and Tycko B: The history of cancer epigenetics. Nat Rev Cancer. 4:143–153. 2004. View Article : Google Scholar : PubMed/NCBI
8	Hilakivi-Clarke L: Estrogens, BRCA1, and breast cancer. Cancer Res. 60:4993–5001. 2000.PubMed/NCBI
9	Stevens KN, Vachon CM and Couch FJ: Genetic susceptibility to triple-negative breast cancer. Cancer Res. 73:2025–2030. 2013. View Article : Google Scholar : PubMed/NCBI
10	Sharma P: Update on the treatment of early-stage triple-negative breast cancer. Curr Treat Options Oncol. 19:22–34. 2018. View Article : Google Scholar : PubMed/NCBI
11	Matsuyama R, Reddy S and Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 24:3490–3496. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lonning PE: Molecular basis for therapy resistance. Mol Oncol. 4:284–300. 2010. View Article : Google Scholar : PubMed/NCBI
13	Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Panopoulos C, Chrissohoou M, Apostolikas N and Efremidis AP: First-line chemotherapy with docetaxel and cisplatin in meta-static breast cancer. Breast. 14:136–141. 2005. View Article : Google Scholar : PubMed/NCBI
14	Jordan P and Carmo-Fonseca M: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 57:1229–1235. 2000. View Article : Google Scholar : PubMed/NCBI
15	Brabec V: DNA modifications by antitumor platinum and ruthenium compounds: Their recognition and repair. Prog Nucleic Acid Res Mol Biol. 71:1–68. 2002. View Article : Google Scholar : PubMed/NCBI
16	Shamseddine AI and Farhat FS: Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy. 57:468–487. 2011. View Article : Google Scholar
17	Sharp CN and Siskind LJ: Developing better mouse models to study cisplatin-induced kidney injury. Am J Physiol Renal Physiol. 313:F835–F841. 2017. View Article : Google Scholar : PubMed/NCBI
18	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
19	Rosenbluh J, Wang X and Hahn WC: Genomic insights into WNT/β-catenin signaling. Trends Pharmacol Sci. 35:103–109. 2014. View Article : Google Scholar
20	Anastas JN and Moon RT: WNT signalling pathways as therapeutic targets in cancer. Nat Rev Canc. 13:11–26. 2013. View Article : Google Scholar
21	Nagahata T, Shimada T, Harada A, Nagai H, Onda M, Yokoyama S, Shiba T, Jin E, Kawanami O and Emi M: Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers. Cancer Sci. 94:515–518. 2003. View Article : Google Scholar : PubMed/NCBI
22	Badawy AM, El-Naga RN, Gad AM, Tadros MG and Fawzy HM: Wogonin pre-treatment attenuates cisplatin-induced nephrotoxicity in rats: Impact on PPAR-γ, inflammation, apoptosis and Wnt/β-catenin pathway. Chem Biol Interact. 308:137–146. 2019. View Article : Google Scholar : PubMed/NCBI
23	Yin P, Song G and Jiang Z: Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1. Cancer Chemother Pharmacol. 81:863–872. 2018. View Article : Google Scholar : PubMed/NCBI
24	Zhao H, Wei W, Sun Y, Gao J, Wang Q and Zheng J: Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. DNA Cell Biol. 34:55–62. 2015. View Article : Google Scholar
25	Zhang X, Liu R, Zhao N, Ji S, Hao C, Cui W, Zhang R and Hao J: Sohlh2 inhibits breast cancer cell proliferation by suppressing Wnt/β-catenin signaling pathway. Mol Carcinog. 58:1008–1018. 2009. View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
27	Krishnamurthy N and Kurzrock R: Targeting the Wnt/beta- catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar
28	Li L, Liu HC, Wang C, Liu X, Hu FC, Xie N, Lü L, Chen X and Huang HZ: Overexpression of β-catenin induces cisplatin resistance in oral squamous cell carcinoma. Biomed Res Int. 2016:53785672016.
29	Zhang B, Liu M, Tang HK, Ma HB, Wang C, Chen X and Huang HZ: The expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in tongue squamous cell carcinoma. J Oral Pathol Med. 41:141–148. 2012. View Article : Google Scholar
30	Naor D, Nedvetzki S, Golan I, Melnik L and Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 39:527–579. 2002. View Article : Google Scholar : PubMed/NCBI
31	Ouhtit A, Rizeq B, Saleh HA, Rahman MM and Zayed H: Novel CD44-downstream signaling pathways mediating breast tumor invasion. Int J Biol Sci. 14:1782–1790. 2018. View Article : Google Scholar : PubMed/NCBI
32	Hubbard AK and Rothlein R: Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med. 28:1379–1386. 2000. View Article : Google Scholar : PubMed/NCBI
33	Pantel K, Schlimok G, Angstwurm M, Passlick B, Izbicki JR, Johnson JP and Riethmüller G: Early metastasis of human solid tumours: Expression of cell adhesion molecules. Ciba Found Symp. 189:157–176. 1995.PubMed/NCBI
34	Elangbam CS, Qualls CW and Dahlgren RR: Cell adhesion molecules-update. Vet Pathol. 34:61–73. 1997. View Article : Google Scholar : PubMed/NCBI
35	Baj G, Arnulfo A, Deaglio S, Tibaldi E, Surico N and Malavasi F: All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression. J Biol Regul Homeost Agents. 13:115–122. 1999.PubMed/NCBI
36	Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U and Milde-Langosch K: Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol. 137:1193–1201. 2011. View Article : Google Scholar : PubMed/NCBI
37	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
38	Zhang Y, Liu B, Zhao Q, Hou T and Huang X: Nuclear localization of β-catenin is associated with poor survival and chemo-/radioresistance in human cervical squamous cell cancer. Int J Clin Exp Pathol. 7:3908–3917. 2014.
39	Yagami T, Yamamoto Y and Koma H: Pathophysiological roles of intracellular proteases in neuronal development and neurological diseases. Mol Neurobiol. 56:3090–3112. 2019. View Article : Google Scholar
40	Lossi L, Castagna C and Merighi A: Caspase-3 mediated cell death in the normal development of the mammalian cerebellum. Int J Mol Sci. 19:pii: E3999. 2018. View Article : Google Scholar : PubMed/NCBI
41	Kim B, Srivastava SK and Kim SH: Caspase-9 as a therapeutic target for treating cancer. Expert Opin Ther Targets. 19:113–127. 2015. View Article : Google Scholar
42	Broxterman HJ, Lankelma J and Hoekman K: Resistance to cytotoxic and anti-angiogenic anticancer agents: Similarities and differences. Drug Resist Updat. 6:111–127. 2003. View Article : Google Scholar : PubMed/NCBI
43	Zhu L, Zou J, Zhao Y, Jiang X, Wang Y, Wang X and Chen B: ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. J Exp Clin Cancer Res. 37:1232018. View Article : Google Scholar